Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Free Cash Flow (2018 - 2019)

DiaMedica Therapeutics (DMAC) has 2 years of Free Cash Flow data on record, last reported at -$1.9 million in Q4 2019.

  • For Q4 2019, Free Cash Flow changed 0.42% year-over-year to -$1.9 million; the TTM value through Dec 2019 reached -$9.1 million, down 58.65%, while the annual FY2024 figure was -$22.1 million, 17.86% down from the prior year.
  • Free Cash Flow reached -$1.9 million in Q4 2019 per DMAC's latest filing, down from -$1.2 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$967000.0 in Q1 2018 and bottomed at -$3.1 million in Q1 2019.